Efficacy of total androgen blockade in metastatic prostatic carcinoma with transient hypogonadotropic hypogonadism: A case report

Giovanni Lo Re, Angela Buonadonna, Mario Duati, Anna Maria Colussi, Vincenzo Canzonieri, Sergio Frustaci, Sandro Morassut, Marino Cimitan, Salvatore Tumolo

Research output: Contribution to journalArticlepeer-review

Abstract

A patient affected by metastatic prostatic carcinoma and hypogonadotropic hypogonadism (HH) was treated with flutamide 750 mg/day plus an LH-RH analog. After confirmation of basal castration during treatment, he continued with antiandrogens alone. Following the normalization of gonadic function and subjective mild bone flare-up, the patient resumed the initial treatment and obtained a partial response. When flutamide was interrupted because of liver toxicity, the patient showed progressive disease in the bone, which was unresponsive to both flutamide resumption and salvage hormone therapy (bicalutamide). The patient is currently receiving chemotherapy with VP16 and estramustine phosphate and is showing both serologic (PSA) and symptomatic response. The interest of this case lies in the incidental detection of HH during therapy and in the responsiveness to treatment.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalTumori
Volume85
Issue number4
Publication statusPublished - Jul 1999

Keywords

  • Hormone therapy
  • Hypogonadism
  • Prostatic carcinoma

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of total androgen blockade in metastatic prostatic carcinoma with transient hypogonadotropic hypogonadism: A case report'. Together they form a unique fingerprint.

Cite this